Abstract
Neovascularization is a hallmark pathology of numerous retinal diseases from diabetic retinopathy (DR) to age-related related macular degeneration (AMD). Over the past 2 decades, the rise of anti-VEGF based medications for neovascular eye conditions has revolutionized the treatment paradigm for patients and preserved the vision of millions. With any form of therapy however, there remain pitfalls and areas for improved interventions. Here, we succinctly present some current views on treatment options for patients with retinal and choroidal neovascularization. We also highlight some of the most promising therapeutic strategies currently being developed and where these therapies may fit with the current clinical standard of care.
Copyright © 2019 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Choroidal Neovascularization / drug therapy*
-
Choroidal Neovascularization / metabolism
-
Choroidal Neovascularization / pathology*
-
Diabetic Retinopathy / drug therapy
-
Diabetic Retinopathy / metabolism
-
Diabetic Retinopathy / pathology
-
Humans
-
Intravitreal Injections
-
Macular Degeneration / drug therapy
-
Macular Degeneration / metabolism
-
Macular Degeneration / pathology
-
Protein Kinase Inhibitors / administration & dosage
-
Retina / drug effects
-
Retina / pathology
-
Retinal Diseases / drug therapy*
-
Retinal Diseases / metabolism
-
Retinal Diseases / pathology*
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Protein Kinase Inhibitors
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A